RBC Capital发起Exact Sciences与Sector Perform合作，Natera与Outperform合作

2025-03-13 22:33

RBC Capital Markets has assumed coverage of Exact Sciences (NASDAQ:EXAS) with SectorPerform and Natera (NASDAQ:NTRA) with Outperform.
NTRA is down about 2% while EXAS is down about 8% in early trade.
RBC has initiated coverage of Natera with $251 price target, as it believes the company is the market leader in the growing and under-penetrated liquid biopsy market.
"NTRA's #1 positions in noninvasive prenatal testing (NIPT) and minimal residual disease (MRD) – oncology cancer Surveillance – gives it first mover advantage as it expands into the adjacent Screening and Selection sectors of oncology liquid biopsy," RBC analysts said.
The research firm also initiated coverage of Exact Sciences with a $52 price target as it believes in the growth of the company in the oncology screening sector of liquid biopsy.
EXAS has fallen 30% in the last twelve months, while NTRA has gained about 60%.

More on Exact Sciences, Natera, etc.